On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Medical research charities LifeArc and Genetics Alliance UK have issued a call to the government to topple obstacles impeding ...

President Donald Trump took time out from the 4th July celebrations in the US to sign his One Big, Beautiful Bill Act (OBBBA) ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format ...

Nearly two years after Takeda pulled its US marketing application for a vaccine against dengue fever, MSD has advanced a rival shot into phase 3. The international MOBILIZE-1 trial is looking at a ...

The pressure to execute a flawless drug or therapy launch has never been greater and continues to lay the foundation for long-term product success. A best-in-class introduction can shape ...

Explore the future of cancer care with a focus on earlier interventions and advancements in oncology care at ASCO 2025. Learn how we are building a stronger future in cancer care.

Major changes to medical device regulations in the UK have come into force with an overhaul of post-market surveillance requirements.

Explore how AI, big data, and machine learning are transforming healthcare advertising in the UK. Discover the potential advancements and trends that await in the year 2025.

As an FDA decision nears from a rival MSD drug, Sanofi is speeding up the rollout of RSV antibody Beyfortus to get ahead of this year's season ...